Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories
-
Form 424B3 Cantor Fitzgerald Income
-
Cantor Fitzgerald Starts Akero Therapeutics (AKRO) at Overweight, 'Positive on Upcoming F4 NASH Readout'
-
Cantor on Lyra Therapeutics (LYRA):'Better-Than-Expected BEACON Results Expand Opportunity for LYRA's CRS Platform'
-
Acelyrin (SLRN) crashes 60% as lead product misses in study; Seen as a 'big positive' for MoonLake (MLTX)
-
CymaBay Therapeutics (CBAY) Prices Upsized $225M Share and Warrant Offering at $17.13/sh
-
CymaBay Therapeutics (CBAY) Announces Proposed $150M Share and Warrant Offering
-
Cantor Fitzgerald Starts Atossa Genetics (ATOS) at Overweight, 'Changing the Treatment Paradigm in Breast Cancer'
-
Form 8-K Cantor Fitzgerald Income For: Sep 06
-
Intuitive Machines (LUNR) Announces $20M Equity Investment
-
Form NPORT-P CANTOR FITZGERALD SUSTAI For: Jun 30
-
Cantor Starts NextGen Healthcare Inc (NXGN) at Overweight, 'attractive investment profile that is not fully reflected'
-
Cantor Fitzgerald Upgrades Ardelyx, Inc (ARDX) to Overweight
-
Connect Biopharma to Participate in Upcoming September Investor Conferences
-
Alpha Tau Medical to Participate in September Investor Conferences
-
Cybin Inc (CYBN) Renews $35M At-The-Market Equity Program
-
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
-
Form N-PX CANTOR FITZGERALD SUSTAI For: Jun 30
-
Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences
-
Borqs Technologies Received Extension from CFIUS for HHE Divestment, and Will Consider Share Buyback and/or Pay a Special Dividend
-
Form N-23C3A CANTOR FITZGERALD SUSTAI For: Aug 18
-
Augmedix Announces Participation in Upcoming Investor Conferences in September 2023
-
BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Spotlighted in New Cantor Fitzgerald Research Brief
-
Arcturus Therapeutics to Attend Upcoming Investor Conferences
-
Orchid Island Capital Announces August 2023 Monthly Dividend and July 31, 2023 RMBS Portfolio Characteristics
-
Form 424B3 Cantor Fitzgerald Income
-
Cantor Fitzgerald Starts Computer Programs and Systems (CPSI) at Overweight
-
Alaunos Therapeutics (TCRT) to wind down its TCR-T Library Phase 1/2 trial and prioritize the hunTR platform
-
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Jun 30
-
Form 13F-NT CANTOR FITZGERALD INVEST For: Jun 30
-
Form 13F-NT Cantor Fitzgerald Europe For: Jun 30
-
Form 13F-NT CANTOR FITZGERALD SECURI For: Jun 30
-
Form 13F-HR CANTOR FITZGERALD, L. For: Jun 30
-
The Metals Company (TMC) Announces $27 Million Registered Direct Offering at $2.00 Per Share Plus Class A Warrants
-
The Metals Company Announces ~US$27 Million Registered Direct Offering at $2.00 Per Share Plus Class A Warrants
-
Form 10-Q Cantor Fitzgerald Income For: Jun 30
-
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
-
Phunware Reports Second Quarter 2023 Financial Results
-
Guanajuato Silver Closes C$8,010,000 "Bought Deal" Financing
-
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
-
Susan Munson and Andrew Davidoff Join Academy Securities as Managing Directors, Rates Liquidity
-
Cantor Fitzgerald Starts Zai Lab (ZLAB) at Overweight
-
Addimmune to Go Public via Merger with 10X Capital Venture Acquisition Corp. III (VCXB)
-
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
-
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
-
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III
-
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III
-
Form S-11 Cantor Fitzgerald Income
-
Tabula Rasa HealthCare (TRHC) to be Acquired by Nautic Partners for $10.50 Per Share, $570 Million